Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

DOI: https://doi.org/10.1177/24755303231195862

Abstract:[This corrects the article DOI: 10.1177/2475530320970538.].

What problem does this paper attempt to address?

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

DOI: https://doi.org/10.1177/24755303231195884

Abstract:[This corrects the article DOI: 10.1177/24755303211029598.].
Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

DOI: https://doi.org/10.1177/24755303231195857

Abstract:[This corrects the article DOI: 10.1177/2475530321995516.].
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

DOI: https://doi.org/10.1177/24755303231195871

Abstract:[This corrects the article DOI: 10.1177/2475530320910466.].
Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

DOI: https://doi.org/10.1177/24755303231195882

Abstract:[This corrects the article DOI: 10.1177/24755303221077211.].
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

DOI: https://doi.org/10.1177/24755303231195863

Abstract:[This corrects the article DOI: 10.1177/2475530320970530.].
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg,Joseph F. Merola,Knut Schäkel,Luis Puig,Patrick D. Mahar,Isabella Yali Wang,Imre Pavo,Christopher Schuster,Christopher E. M. Griffiths

DOI: https://doi.org/10.3389/fmed.2023.1171132

IF: 3.9

2023-03-10

Frontiers in Medicine

Abstract:[This corrects the article DOI: 10.3389/fmed.2022.1092688.].

medicine, general & internal
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

DOI: https://doi.org/10.1177/24755303231195864

Abstract:[This corrects the article DOI: 10.1177/2475530320925067.].
Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

DOI: https://doi.org/10.1177/26335565231223601

2023-12-01

Journal of Multimorbidity and Comorbidity

Abstract:[This corrects the article DOI: 10.1177/26335565231212336.].
Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

DOI: https://doi.org/10.1177/24755303231195868

Abstract:[This corrects the article DOI: 10.1177/24755303211051724.].
Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

DOI: https://doi.org/10.1177/24755303231195883

Abstract:[This corrects the article DOI: 10.1177/24755303211037308.].
Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

DOI: https://doi.org/10.1177/24755303231195867

Abstract:[This corrects the article DOI: 10.1177/24755303221131257.].
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

DOI: https://doi.org/10.1177/24755303231195874

Abstract:[This corrects the article DOI: 10.1177/24755303211056059.].
Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

DOI: https://doi.org/10.2147/JIR.S499600

2024-10-11

Abstract:[This corrects the article DOI: 10.2147/JIR.S472417.].
Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

DOI: https://doi.org/10.1177/24755303231196711

Abstract:[This corrects the article DOI: 10.1177/2475530320950290.].
Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

DOI: https://doi.org/10.1177/24755303231195869

Abstract:[This corrects the article DOI: 10.1177/2475530320950265.].
Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

DOI: https://doi.org/10.1177/24755303231195872

Abstract:[This corrects the article DOI: 10.1177/24755303211011477.].
Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

DOI: https://doi.org/10.1177/24755303231195885

Abstract:[This corrects the article DOI: 10.1177/2475530320954279.].
Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

C. A. M. van Riel,C. A. J. Michielsens,M. E. van Muijen,L. S. van der Schoot,J. M. P. A. van den Reek,E. M. G. J. de Jong

DOI: https://doi.org/10.3389/fphar.2024.1505626

IF: 5.6

2024-10-15

Frontiers in Pharmacology

Abstract:This article is a correction to: Dose reduction of biologics in patients with plaque psoriasis: a review

pharmacology & pharmacy
Corrigendum to "The treatment of primary biliary cholangitis: from shadow to light"

DOI: https://doi.org/10.1177/17562848241277276

2024-08-31

Abstract:[This corrects the article DOI: 10.1177/17562848241265782.].
Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

DOI: https://doi.org/10.1177/24755303231195875

Abstract:[This corrects the article DOI: 10.1177/24755303221099292.].

Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Corrigendum to "The treatment of primary biliary cholangitis: from shadow to light"

Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options